-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, IfwSpSQIFzJHhvlzqH4eas/DowkUUNxClC+ljc7HjORMrTxND7tiZufpRMehdmdJ Qe9mMUtjrMp7H74Omty7LQ== 0000927016-97-001854.txt : 19970708 0000927016-97-001854.hdr.sgml : 19970708 ACCESSION NUMBER: 0000927016-97-001854 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19970707 SROS: NASD SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: MILLENNIUM PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001002637 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043177038 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-49167 FILM NUMBER: 97636870 BUSINESS ADDRESS: STREET 1: 640 MEMORIAL DR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6176797000 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: PERSEPTIVE BIOSYSTEMS INC CENTRAL INDEX KEY: 0000859640 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 042987616 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 500 OLD CONNECTICUT PATH CITY: FRAMINGHAM STATE: MA ZIP: 01701 BUSINESS PHONE: 5083837700 MAIL ADDRESS: STREET 1: 500 OLD CONNECTICUT PATH CITY: FRAMINGHAM STATE: MA ZIP: 01701 SC 13D/A 1 AMEND NO. 1 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1)/1/ Millennium Pharmaceuticals, Inc. - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock, $.001 par value - -------------------------------------------------------------------------------- (Title of Class of Securities) 0005999021 ---------------------------------------- (CUSIP Number) Samuel P. Hunt, III, Esq., PerSeptive Biosystems, Inc. 500 Old Connecticut Path, Framingham, MA 01701 - -------------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) June 19, 1997 ---------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box [_]. NOTE: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent. - -------------- /1/ The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). SCHEDULE 13D CUSIP No. 0005999021 Page 2 of 5 Pages - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON PerSeptive Biosystems, Inc., 04-2987616 - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) |__| (b) |__| - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* SC - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) |__| - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER NUMBER OF 806,291 -------------------------------------------------------------------- SHARES 8 SHARED VOTING POWER BENEFICIALLY OWNED BY -0- -------------------------------------------------------------------- EACH 9 SOLE DISPOSITIVE POWER REPORTING PERSON 806,291 -------------------------------------------------------------------- WITH 10 SHARED DISPOSITIVE POWER -0- - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 806,291 - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [_] - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 2.81% - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON * CO - -------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION. SCHEDULE 13D CUSIP No. 0005999021 Page 3 of 5 Pages This Schedule 13D Amendment No. 1 amends the Schedule 13D filed on February 20, 1997 with the Securities and Exchange Commission (the "SEC") on behalf of PerSeptive Biosystems, Inc. ("PerSeptive") to reflect the sale of 806,291 shares of Issuer Common Stock by PerSeptive. ITEM 5. INTEREST IN SECURITIES OF THE ISSUER Item 5 is amended and restated in its entirety to read as set forth below: (a) Amount Beneficially Owned: PerSeptive beneficially owns 806,291 shares of Issuer Common Stock. Percent of Class: PerSeptive owns 2.81% of Issuer Common Stock. (b) Number of Shares as to which such person has: (i) sole power to vote or direct the vote: 806,291 shares (ii) shared power to vote or direct the vote: NOT APPLICABLE (iii)sole power to dispose or to direct the disposition of: 806,291 shares (iv) shared power to dispose or to direct the disposition of: NOT APPLICABLE (c) Except as set forth herein, neither PerSeptive, nor, to PerSeptive's knowledge, any person named in Schedule I, has effected any transaction in the Issuer Common Stock during the past 60 days. (d) Not applicable. (e) Not applicable. SCHEDULE 13D CUSIP No. 0005999021 Page 4 of 5 Pages After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and current. Date: June 30, 1997 PERSEPTIVE BIOSYSTEMS, INC. /s/ John F. Smith ___________________________ John F. Smith President SCHEDULE 13D CUSIP No. 0005999021 Page 5 of 5 Pages
SCHEDULE I ---------- Name and Address of Corporation or Other Principal Occupation Organization in Which Name or Employment Employed - ------------------------ ---------------------- ------------------------ Noubar B. Afeyan, Ph.D. Chief Executive PerSeptive Biosystems, Inc. Officer, Director and 500 Old Connecticut Path Chairman of the Board Framingham, MA 01701 John F. Smith President and Director PerSeptive Biosystems, Inc. 500 Old Connecticut Path Framingham, MA 01701 Thomas G. Ruane Senior Vice President, PerSeptive Biosystems, Inc. Chief Financial 500 Old Connecticut Path Officer and Treasurer Framingham, MA 01701 Bruce J. Ryan Director Amdahl Corporation 1250 East Arques Avenue (M/S 104) P.O. Box 3470 Sunnyvale, CA 94088-3470 Daniel I.C. Wang, Ph.D. Director Massachusetts Institute of Technology 18 Vassar Street Building 20A Room 207 Cambridge, MA 02139 Edwin M. Kania, Jr. Director One Liberty Ventures One Liberty Square Boston, MA 02109 William F. Pounds, Ph.D. Director MIT Sloan School of Management 50 Memorial Drive E52-472 Cambridge, MA 02142
-----END PRIVACY-ENHANCED MESSAGE-----